Healthcare is becoming more complex, chaotic, and fragmented. The complexity and fragmentation of human resources within the healthcare system and the freedom of speech across professional social media demand a better understanding of all challenges and opportunities.

Promoters are now required to adjust their level of understanding of different HCP organizations, which operate with more debate, divergence, and conflicting values to gauge effect size, relative effectiveness, and clinical relevance of a given improvement. We strongly believe that early anticipation of small changes to clinical trial design helps enhance value at a reasonable cost for promoters.

Furthermore, there is a growing need for more quantitative and qualitative analysis of trade-offs and exhaustive evaluation of all relevant variables far beyond the classical criticism of trial endpoints.

This is at the core of our analysis, which is also driven by a strong internal clinical/scientific experience and a positive philosophy towards patient experience and empowerment1, 2, 3.

Illustration - Clinical effectiveness
Clinical effectiveness

1.    Tchobroutsky, G (1997). Wong, O as co-author of Chapters 16, 19, and 47. Des symptômes à la décision. 3e edition. Arnette Blackwell.
2.    Tchobroutsky, G. and Wong, O. (1996) Le métier de médecin. Paris: Presses universitaires de France. Le metier de medecin - Poche - Georges Tchobroutsky, O. Wong - Achat Livre | fnac
3.    Tchobroutsky, G. and Wong, O. (1995) Que sais-je - La Santé. Paris: Presses universitaires de France. La sante - broché - Georges Tchobroutsky, O. Wong - Achat Livre | fnac
4.    Rakel, R.E., Rakel, D.P. and Ahmed, S.M. (2016) Textbook of family medicine. Philadelphia: Elsevier/Saunders.
5.    Wong, O. and Bamforth, I. (1999) “Negotiating decisions with patients,” The Lancet, 353(9163), pp. 1531–1532. Available at:
6.    Dr. Olivier Wong as author of 27 viewpoints for “Le Generaliste” (1993 to 2012)
7.    Martinez, L., Consoli, M. S., Monnier, L., Simon, D., Wong, O., Yomtov, B., Guéron, B., Benmedjahed, K., Guillemin, I., and Arnould, B. (2007) “Studying the hurdles of insulin prescription (ship©): Development, scoring and initial validation of a new self-administered questionnaire,” Health and Quality of Life Outcomes, 5(1). Available at: 
8.    Mullani, N. (2019) “An RNA Signature Links Oxidative Stress To Cellular Senescence. Molecular biology”. Sorbonne Université. ⟨NNT : 2019SORUS560⟩ ⟨tel-03139803⟩. Available at: An RNA Signature Links Oxidative Stress To Cellular Senescence - TEL - Thèses en ligne (
9.    Mullani, N. et al. (2021) “Reduced RNA turnover as a driver of cellular senescence,” Life Science Alliance, 4(3). Available at: 
10.    Mullani, N. et al. (2016) “Caspase-9 inhibitor Z-Lehd-FMK enhances the yield of in vitro produced buffalo (bubalus bubalis) pre-implantation embryos and alters cellular stress response,” Research in Veterinary Science, 104, pp. 4–9. Available at:
11.    Sharma, A., Agrawal, H., Mullani, N., Sandhu, A., Singh, M. K., Chauhan, M. S., Singla, S. K., Palta, P., and Manik, R. S. (2015) “Supplementation of Tauroursodeoxycholic acid during IVC did not enhance in vitro development and quality of buffalo IVF embryos but combated endoplasmic reticulum stress,” Theriogenology, 84(2), pp. 200–207. Available at:
12.    Delmas, C. (2021) Rôle de la protéine Delta-like homologue 1 (DLK1) sur la croissance postnatale et le développement de l’axe somatotrope. Sorbonne Université. Thesis.
13.    Speakers and panelist at many HTA / HEOR / regulatory international and national conferences 

Our firm collects your personal data in order to respond your request. Please fill in all the required fields. If you wish to access, delete or modify your data, please send an email to including "MY DATA" in the subject header.


27 rue Blomet
75015 Paris
+33 (0)9 66 97 82 58